Can-Fite BioPharma Ltd.
CANFNYSE
$3.40
↑ +2.4%Jul 17 close · end-of-day
Price
1Y↓ -83.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$5.6M
Enterprise Value
$68,107.20
P/E
—
P/S
13.8
P/B
1.0
EV/EBITDA
—
PEG
—
FCF Yield
-159.9%
Dividend Yield
—
Revenue (TTM)
$405,000.00
Net Income (TTM)
-$9.8M
Free Cash Flow (TTM)
-$9.0M
Gross Margin
—
Operating Margin
-2456.8%
Net Margin
-2426.7%
ROE
-175.8%
ROIC
-12477.0%
Debt / Equity
—
Net Cash
$5.5M
Return 1Y
-83.7%
Company profile
Can-Fite BioPharma Ltd. develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the. treatment of psoriasis; and Phase II clinical trials for COVID-19. It also develops Namodenoson that is in Phase III. trial for. hepatocellular carcinoma, as well as in Phase IIb trial for treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial.
- CEO
- Pnina Fishman
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 8
- Website
- canfite.com
Earnings
No reported earnings periods on file.
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $763,000.00 | $853,000.00 | $810,000.00 | $743,000.00 | $674,000.00 | $405,000.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$14.1M | -$12.8M | -$10.1M | -$8.2M | -$8.1M | -$9.9M |
| Net income | -$14.4M | -$12.6M | -$10.2M | -$7.6M | -$7.9M | -$9.8M |
| Diluted EPS | -$0.04 | -$0.03 | -$0.01 | -$17.92 | -$10.86 | -$5.97 |
| Operating cash flow | -$12.1M | -$9.9M | -$10.8M | -$8.4M | -$7.6M | -$8.9M |
| Free cash flow | -$12.1M | -$9.9M | -$10.8M | -$8.4M | -$7.6M | -$9.0M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -1853.1% | -1505.5% | -1246.4% | -1103.0% | -1206.2% | -2456.8% |
| Net margin | -1892.9% | -1478.9% | -1255.9% | -1027.5% | -1169.1% | -2426.7% |
No quarterly data.
Company news
Jul 1, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.